Skip to main content

Medicenna Therapeutics Corp. (MDNA)

NASDAQ: MDNA · IEX Real-Time Price · USD
2.48 -0.05 (-2.02%)
Oct 22, 2021 9:53 AM EDT - Market open
Market Cap140.92M
Revenue (ttm)n/a
Net Income (ttm)-21.32M
Shares Out53.55M
EPS (ttm)-0.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,679
Open2.52
Previous Close2.53
Day's Range2.45 - 2.52
52-Week Range1.85 - 6.84
Beta0.53
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 12, 2021

About MDNA

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to tr...

IndustryBiotechnology
Employees13
Stock ExchangeNASDAQ
Ticker SymbolMDNA
Full Company Profile

Financial Performance

Financial Statements

News

Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference

-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP)

2 weeks ago - GlobeNewsWire

Medicenna Appoints Dr. John H. Sampson to its Board of Directors

Announces Results of Annual Meeting of Shareholders Announces Results of Annual Meeting of Shareholders

4 weeks ago - GlobeNewsWire

Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit

TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

1 month ago - GlobeNewsWire

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study

-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors

1 month ago - GlobeNewsWire

Medicenna Therapeutics to Present at Upcoming September Investor Conferences

TORONTO and HOUSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

1 month ago - GlobeNewsWire

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights

-- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021

2 months ago - GlobeNewsWire

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...

2 months ago - GlobeNewsWire

Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Dig...

-  Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors

2 months ago - GlobeNewsWire

Medicenna's IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability t...

-- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improve...

3 months ago - GlobeNewsWire

Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021

3 months ago - GlobeNewsWire

Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights

-- Management hosting conference call and webcast today at 8:30 AM ET

4 months ago - GlobeNewsWire

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

TORONTO and HOUSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the ...

5 months ago - GlobeNewsWire

Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent...

-- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma

5 months ago - GlobeNewsWire

Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer

TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

6 months ago - GlobeNewsWire

Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

6 months ago - GlobeNewsWire

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cyt...

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

6 months ago - GlobeNewsWire

Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at th...

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

6 months ago - GlobeNewsWire

Medicenna Therapeutics to Present at Upcoming March Investor Conferences

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...

7 months ago - GlobeNewsWire

Medicenna to Present at the Cowen 41st Annual Healthcare Conference

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...

8 months ago - GlobeNewsWire

Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...

8 months ago - GlobeNewsWire

Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its fi...

8 months ago - GlobeNewsWire

Medicenna Establishes At-the-Market Sales Facility

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today th...

9 months ago - GlobeNewsWire